Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
2 out of 3
people prescribed antidepressants are women[1]
There's a story behind each one of the numbers...
11,109,000
people received a mental health prescription in the UK during 2021[1]
"I’m very hopeful that in the months to come KRN-101 will be the start of something amazing"
Chief Medical Oficer
Dr Malcolm Barratt-Johnson
A patient-first approach
Albert Labs is a pharmaceutical company focused on natural neurological therapies to treat the immediate, unmet needs of the ever-worsening mental health crisis.
A breakthrough for mental health
Studies have displayed psilocybin as a breakthrough for mental health care. Read about our natural psilocybin medicine: KRN-101.
Rethinking the clinical trial paradigm
Traditional clinical trial infrastructure means people currently suffering could be waiting 5 or more years for psilocybin therapy to be available to them.
Albert Labs is strategically placed in the UK, where innovative licensing and access programs are available. These programs also provide a pathway to the rest of the world.
UK clinical focus, supported by our Canadian and Portuguese research & development laboratories.
It is our promise to deliver our innovative mental health medicine to patients with urgent and unmet needs.
“Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.”
Dr. Michael Raymont, CEO
Faster
Real-World Evidence can accelerate innovation and access for patients currently suffering from unmet needs. A clinical pathway previously used for Covid-19 vaccines and cancer treatments in the UK.
Scalable
Leveraging existing clinic & research infrastructure and preidenitfied, accessible patient pools, through collaboration with established hospital networks.
Credible
Strategically placed in the UK to make use of the Real-World Evidence protocol, which provides crucial data and insights for licensing & regulation of prescribed medicine.
Focused
Patient-centric data and early clinician engagement will build and deliver these breakthroughs safely and effectively to those most in need.
For the patients suffering most
Tens of millions of people are diagnosed with cancer each year, and millions more are living with it. The depression and anxiety that might accompany cancer is self-evident, more commonly known as cancer distress.
Worry, sleeplessness, fear, and doubts regarding the meaning of one’s life are commonplace with a cancer diagnosis.
Due to the complexities surrounding cancer therapy, too often, patients’ psychological needs are left untreated.
Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related distress.
Meet our team
Everyone has been impacted by mental health and our expert team is no exception. We know the immense struggle and we endeavour to find better solutions for all.
Our people bring experience and expertise across multiple fields to deliver a scalable solution to the mental health crisis.
Professor Joanna Neill
Chair, Clinical Advisory Board
“Psychedelic therapy heals people. Thats really not something I’ve seen us do in psychiatry in all my career”[8]
Professor Sara Tai
Principal Investigator
“I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy and psilocybin. ”[9]
Dr Malcolm Barratt-Johnson
Chief Medical Officer
“It is an extremely exciting time for Albert Labs, we’re looking forward to treating our first patients with our product.”[10]
The history
PSILOCYBIN
sil-uh-sahy-bin
Psilocybin is a naturally occuring tryptamine alkaloid found in over 200 species of fungi. It is a serotonin 2A receptor agonist, which after a single dose can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness. Imagery found on prehistoric murals suggests that human usage of psilocybin mushrooms predates recorded history.
1958
Sandoz Laboratory Basel, Switzerland
Albert Hofmann, a Swiss chemist, pioneered the development & isolation of psilocybin. Understanding its therapeutic value first-hand. [11]
1960
Sandoz introduced Indocybin™
Marketed by Sandoz as Indocybin™ for psychopharmacological and therapeutic clinical research. [12]
1971
United Nations Treaty - Convention on psychotropic substances
Set up to control psychoactive drugs such as amphetamine-type stimulants, barbiturates, benzodiazepines, and psychedelics. Despite psilocybin’s utility as a medical therapy it was scheduled in the highest class, resulting in the discontinuation of medical research. [13]
35 Years later
2006
Moreno et al, at the University of Arizona
The team concluded that in a controlled clinical environment, psilocybin was safely used in 9 subjects with Obsessive Compulsive Disorder (OCD) and was associated with acute reductions in cores symptoms.[14]
2012
R Carhart-Harris et al, at Imperial College London
30 healthy volunteers had psilocybin infused into their blood while inside magnetic resonance imaging (MRI) scanners, which measure changes in brain activity. The effects need to be investigated further but we must be interested in exploring psilocybin’s therapeutic potential. [16]
2016
R Griffiths et al, at Johns Hopkins School of Medicine
The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. High-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. [17]
2011
C Grob et al, at UCLA School of Medicine
Dr Grob investigated the clinical application of psilocybin in the treatment of anxiety reactive to advanced-stage cancer. In a double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, the active group showed clear mood improvements compared to the control. [15]
2016
S Ross et al, at NYU School of Medicine
29 patients with cancer-related anxiety and depression were dosed with psilocybin or active-placebo, both in conjunction with psychotherapy. psilocybin arm produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness.
At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety. [18]
Studies have displayed psilocybin as a breakthrough for mental health care [2]
Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.
